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Abstract: Epidermal growth factor receptor (EGFR) and MEK inhibitors (EGFR/MEKi) are 
beneficial for the treatment of solid cancers but are frequently associated with severe therapy-
limiting acneiform skin toxicities. The underlying molecular mechanisms are poorly 
understood. Using gene expression profiling we identified IL-36γ and IL-8 as candidate 
drivers of EGFR/MEKi skin toxicity. We provide molecular and translational evidence that 
EGFR/MEKi in concert with the skin commensal bacterium Cutibacterium acnes act 
synergistically to induce IL-36γ in keratinocytes and subsequently IL-8, leading to cutaneous 
neutrophilia. IL-36γ expression was the combined result of C. acnes-induced NF-κB 
activation and EGFR/MEKi-mediated expression of the transcription factor Krüppel-like 
factor 4 (KLF4), due to the presence of both NF-κB- and KLF4-binding sites in the human 
IL-36γ gene promoter. EGFR/MEKi increased KLF4 expression by blockade of the EGFR-
MEK-ERK pathway. These results provide an insight into understanding the pathological 
mechanism of the acneiform skin toxicities induced by EGFR/MEKi and identify IL-36γ and 
the transcription factor KLF4 as potential therapeutic targets.   
  
Introduction 
Agents targeting the epidermal growth factor receptor (EGFR)-mediated signaling pathway 
are increasingly used for the treatment of advanced lung, pancreatic, colorectal and head and 
neck cancers, which benefit from exacerbated EGFR activity for their growth and survival (1, 
2). Small molecule inhibitors of the Mitogen-activated protein kinases (MAPKs) signaling 
pathways including extracellular signal-regulated kinase (ERK) and MAPK/ERK kinase 
(MEK) 1 and 2 have also shown their efficacy in the treatment of various cancers, especially 
melanoma (3, 4).  
One significant clinical limitation to the prolonged use of EGFR and MEK inhibitors 
(EGFR/MEKi) is the occurrence of skin toxicities in 50-80% of patients, including an 
acneiform eruption that usually develops within the first few weeks of therapy (4-6). The first 
monoclonal antibody and small molecule inhibitor of EGFR were approved by the FDA for 
the treatment of cancer twelve and thirteen years ago respectively, and since then skin 
toxicities induced by these drugs remain unsolved problems. Even though topical or oral 
agents alone or in combination are used to treat skin toxicities and show some efficacy, 
EGFR/MEKi-induced skin acneiform eruptions can still seriously affect patients’ quality of 
life, leading physicians to reduce the dose administered or discontinue therapy in severe skin 
toxicity cases (7-9). Importantly, the development and severity of the acneiform eruption have 
been shown to correlate with favorable anti-tumor responses (10-12). 
The exact molecular pathogenesis underlying the frequent and rapid development of 
skin toxicity to EGFR/MEKi is not understood to date. Animal studies using mice selectively 
lacking EGFR in the skin revealed that EGFR signaling is critical for normal skin barrier 
function and antimicrobial defense (13, 14). However, the phenotype of mice selectively 
lacking EGFR in the skin resembles atopic dermatitis and is distinct from the acneiform skin 
toxicity seen in patients treated with EGFR/MEKi (15, 16). In humans, histopathology of 
acneiform eruption lesions is characterized by folliculitis with massive infiltration of 
neutrophils histologically resembling acne vulgaris (5). Another feature of acneiform 
toxicities caused by EGFR/MEKi and shared with acne vulgaris is the topographical 
predominance of inflammation in skin areas rich in pilosebaceous units, also corresponding to 
sebum-rich regions of the skin, such as the central face, upper chest, and back (17-21). These 
sebum-rich regions are highly colonized by Cutibacterium acnes (C. acnes, formerly known 
as Propionibacterium acnes) a lipophilic commensal representing the most abundant 
microorganism on the skin of healthy adults (19-22). While C. acnes is thought to play an 
important role in common acne, its involvement in EGFR/MEKi acneiform toxicities has 
never been investigated. 
A better understanding of the molecular pathogenesis of acneiform eruption by 
EGFR/MEKi is still needed so as to guide the development of effective therapies to prevent or 
suppress the skin toxicity, while preserving their anti-tumor effects. Here, we investigate the 
molecular mechanisms of acneiform eruption associated with EGFR/MEKi.  
Results  
Skin gene expression profiling in EGFRi-induced acneiform skin toxicity  
Employing an unbiased approach, we performed gene expression profiling of lesional skin 
biopsy samples from patients suffering from acneiform eruption by EGFRi (Figure 1A and 
Supplemental Table 1). We found elevated IL-8 and IL-36γ in the patients’ skin, whereas 
important inflammatory cytokines such as TNF-α, IL-6 and IL-17A were not significantly 
upregulated when compared to skin from healthy donors (Figure 1A). This observation was 
further confirmed by quantitative PCR with more lesional skin samples (Figure 1B and 
Supplemental Figure 1A). As previously reported, the expression of antimicrobial peptides 
such as RNase7 was also found to be decreased in patients’ skin (14) (Supplemental Figure 
1A). IL-36γ is a proinflammatory cytokine of the IL-1 family, predominantly expressed by 
keratinocytes and is able to signal in an auto- or paracrine manner through the IL-36 receptor 
(also known as IL1RL2) and activates NF-κB signaling pathway in target cells. It has recently 
been shown that IL-36 plays a role in the cutaneous neutrophilic pustular autoinflammatory 
disease called DITRA (Deficiency of the IL-36 receptor antagonist) (23, 24). Interestingly, 
IL-36γ has been demonstrated to induce prominent production of the potent neutrophil 
chemoattractant IL-8 (25), which would be compatible with the extensive infiltration of 
neutrophils seen in skin lesions from patients suffering from acneiform eruptions (5). 
Furthermore, clinical trial data has shown that subcutaneous anti-IL-8 antibody injection 
strongly abrogates the induction of acneiform skin toxicity by EGFRi (26). To define the cell 
types expressing IL-36γ in the skin of patients with acneiform eruption, immunohistochemical 
analyses and mRNA in situ hybridization were performed. In line with gene expression data, 
histochemical analysis of patients’ lesions revealed elevated IL-36γ expression, which was 
predominantly localized in keratinocytes of epidermal hair follicles (Figure 1C and 
Supplemental Figure 1B-C). This result and the fact that EGFR is preferentially expressed in 
undifferentiated and proliferating keratinocytes in the basal and suprabasal layers of the 
epidermis as well as the outer layers of the hair follicle (5), led to the hypothesis that 
keratinocytes might be key players in the acneiform eruption by producing IL-36γ in response 
to EGFRi. 
EGFRi and C. acnes synergize to promote IL-36γ expression and skin inflammation  
To examine whether EGFR inhibition could lead to enhanced IL-36γ production in 
keratinocytes, primary human keratinocytes (PHKs) were exposed to the EGFRi erlotinib in 
vitro. Upon exposure to 1 μM erlotinib - a concentration compatible with the serum 
concentration found in treated patients (27) - PHKs produced 3.2-fold (p=0.048) higher levels 
of IL-36γ than upon exposure to vehicle alone as quantified by RT-PCR (Figure 1D). Given 
that both common acne vulgaris and EGFRi-induced eruptions occur in sebum-rich regions of 
the body that are colonized with C. acnes, and that C. acnes is known to be involved in the 
pathogenesis of acne (19-22), we exposed PHKs to both erlotinib and C. acnes. Interestingly, 
IL-36γ production at the mRNA and protein level was further enhanced (8.4-fold in mRNA, 
p=0.001) when PHKs were simultaneously exposed to erlotinib and C. acnes (Figure 1D-E). 
In contrast, the transcripts of other inflammatory cytokines such as TNF-α, IL-1β and IL-6 
were not significantly increased by simultaneous exposure to erlotinib and C. acnes (Figure 
1D). Similar levels of IL-36γ induction in PHKs were also observed with cetuximab, another 
EGFRi, when used in combination with C. acnes (Supplemental Figure 1D). Furthermore, 
these results were confirmed when EGFR was genetically silenced using siRNA 
(Supplemental Figure 1E). 
Besides IL-36γ, expression of other genes were significantly increased in acneiform 
lesions by EGFRi, including the S100 proteins S100A12 and S100A8, the chemokine CXCL6 
and the pleiotropic immunomodulatory cytokine IL-24 (Figure 1A). The regulation of the 
expression of these genes by erlotinib and C. acnes was also assessed in PHKs, and with the 
exception of S100A8, the expression of these genes was not as elevated as that of IL-36γ 
(Supplemental Figure 1F). However, the expression of the above transcripts could be 
significantly induced in PHKs by exposure for 6 hours to IL-36γ alone (Supplemental Figure 
1G), suggesting that IL-36γ may be an upstream driver cytokine in EGFRi-induced acneiform 
eruption. 
Similar to exposure to the TLR2 agonist C. acnes (28-30), IL-36γ release into the 
culture supernatant of PHKs could be induced by exposure to erlotinib and the TLR2 agonist 
Pam3CSK4 (Figure 1F). In line with this, knocking down TLR2 attenuated IL-36γ production 
induced by erlotinib and C. acnes (Supplemental Figure 1H-I). Expression of the neutrophil 
chemoattractant IL-8 has previously been shown to be induced by IL-36γ (23, 25, 31-35) and 
was also found by gene expression profiling and quantitative PCR to be upregulated (32-fold, 
p=0.041) in acneiform lesional skin (Figure 1B). To determine if simultaneous EGFR 
inhibition and TLR2 signaling can trigger IL-36γ-dependent production of IL-8 in human 
skin, we exposed normal human skin ex vivo to erlotinib and Pam3CSK4. In line with the 
neutrophil-rich inflammation and enhanced IL-8 gene expression observed in acneiform 
lesional skin by EGFRi, increased IL-8 production (16-fold, p=0.0051) was observed in 
human skin explants exposed to erlotinib and Pam3CSK4 as compared to vehicle, erlotinib or 
Pam3CSK4 alone (Figure 1G). In the same ex vivo experimental setting, addition of the 
recombinant IL-36 receptor antagonist to erlotinib and Pam3CSK4 resulted in a significant 
reduction of IL-8 production (4.1-fold, p=0.014) (Figure 1G), thus establishing the IL-36 
dependency of IL-8 expression in human skin exposed simultaneously to EGFRi and TLR2 
agonists. These data demonstrate that EGFR inhibition and simultaneous TLR2 activation act 
synergistically to drive keratinocyte IL-36γ expression with subsequent production of the 
neutrophil chemoattractant IL-8 in the skin. Taken together with the observed high levels of 
expression of IL-36γ and the neutrophil-rich inflammation observed in the pilo-sebaceous 
units of inflamed skin by EGFRi, this is suggestive of a central pathogenic role of 
keratinocyte-derived IL-36γ in the acneiform skin toxicity caused by EGFRi.   
Increased expression and binding of the transcription factor KLF4 to the IL-36γ promoter 
upon EGFR inhibition 
To understand how EGFRi and TLR2 signaling synergistically promote IL-36γ production in 
PHKs, we analyzed the transcriptional regulation of human IL-36γ. Histone modification 
patterns in PHKs revealed one enhancer and one promoter region upstream of the IL-36γ 
gene, the promoter region containing a binding site for the NF-κB subunit p65 (36) 
(Supplemental Figure 2A). Interestingly, EGFR inhibition alone, or C. acnes exposure alone, 
resulted in only moderate enhancement of IL-36γ reporter activity as assessed in a Luciferase 
reporter assay of human IL-36γ transcriptional activity in PHKs (Figure 2A). This is 
suggestive of the existence of two distinct responsive sites in the promoter region of the IL-
36γ gene. In response to EGFR inhibition and C. acnes exposure, the activation pattern of a 
reporter containing both the IL-36γ enhancer and promoter regions was similar to the pattern 
observed when only the promoter was present (Supplemental Figure 2B), suggesting that the 
enhancer region is dispensable for erlotinib and C. acnes-induced IL-36γ production in PHKs. 
Therefore, and given the synergistic effect of erlotinib and C. acnes, this observation suggests 
that the IL-36γ promoter contains a binding site for an additional transcription factor to NF-
κB p65. To identify this site, we generated IL-36γ reporters with promoter deletions of 
increasing lengths, thus mapping a genomic region located within 1130 and 1100 bp upstream 
of the first ATG as crucial for IL-36γ transcriptional activity (Figure 2B-C). Furthermore, 
reporters containing mutations in either the genomic region located between 1130 and 1100 
bp upstream of the first ATG or within the p65-binding site revealed, respectively, a 42% 
(p=0.010) and 81% (p=0.0003) reduction in IL-36γ transcriptional activity, whereas mutation 
of both regions resulted in a 92% (p=0.0002) reduction (Figure 2D-E), indicating that both 
regions are required for optimal IL-36γ transcriptional activity. 
To identify the putative transcription factor that binds to the -1130 to -1100 bp region 
of the IL-36γ gene promoter, we searched the JASPAR database, an open-access repository 
for matrix-based transcription factor binding profiles (37), and identified fourteen 
transcription factors as potential candidates (Supplemental Figure 2C). As no NF-κB-related 
transcription factors were revealed by this search, we hypothesized that the EGFRi-responsive 
site (EiRS) is located in this -1130 to -1100 bp region of the IL-36γ gene promoter. We 
subsequently performed quantitative PCR of mRNA derived from keratinocytes exposed to 
EGFR inhibitor erlotinib, and amongst these 14 candidates thereby identified a significant 
change in the expression levels of two transcription factors, KLF4 and ZEB1 (Figure 2F). 
Since ZEB1 transcription decreased after EGFR inhibition, and is weakly expressed in normal 
keratinocytes (refs. 38, 39 and Supplemental Figure 2D), we considered KLF4 as the probable 
candidate and assessed whether KLF4 could effectively bind to the EGFRi responsive region 
of the IL-36γ promoter. Using an electrophoretic mobility shift assay (EMSA), we could 
effectively demonstrate that KLF4 specifically binds to the DNA sequence within the -1130 
to -1100 bp region of the IL-36γ gene promoter (Figure 2G). In line with the above, EGFR 
inhibition resulted in increased KLF4 expression in PHKs (Figure 2H), and DNA pull down 
assays performed with the same sequence as previously used in the EMSA revealed that 
KLF4 from erlotinib-exposed PHKs could specifically bind to the EGFR inhibitor-responsive 
region located between -1130 to -1100 bp upstream of the ATG in the IL-36γ gene promoter 
(Figure 2I). In addition, exposure of human skin ex vivo to erlotinib increased the expression 
of KLF4 (Figure 2J).  
Lack of a KLF4 binding site in the mouse IL-36γ promoter precludes murine EGFRi-induced 
IL-36γ response 
Next, we examined IL-36γ production in response to EGFRi and NF-κB activation in primary 
murine keratinocytes (PMKs). Surprisingly, despite the ability of the EGFR inhibitor erlotinib 
to block the phosphorylation of murine EGFR to a similar extent to that of human EGFR 
(Supplemental Figure 3A), enhanced IL-36γ production was not observed, in contrast to the 
effect observed in human keratinocytes (Figure 3A). In this setting, PMKs were exposed to 
murine IL-36γ to achieve NF-κB activation given their weak response to C. acnes, 
Pam3CSK4 and lipopolysaccharide (LPS) (data not shown). In our culture conditions, PMKs 
already expressed high levels of KLF4 at the basal state (Supplemental Figure 3B), a 
characteristic that was irrespective of the numerous culture conditions tested (data not 
shown). To test the requirement of KLF4 for IL-36γ transcription in mouse keratinocytes, we 
compared PMKs from KLF4-knockout mice and wild-type mice, and PMKs overexpressing 
KLF4, however, without being able to detect synergistic IL-36γ elevation after NF-κB 
activation as observed in human keratinocytes (Figure 3B and Supplemental Figure 3C). In 
accordance with the above, the putative KLF4 binding site identified by searching the 
JASPAR database, located at 1140 bp upstream of the first ATG in murine IL-36γ promoter 
(Figure 3C), could not be shown by EMSA to form a DNA-protein complex with mouse 
KLF4 (Figure 3D). Analysis of evolutionarily conserved regions in the genomes of sequenced 
species revealed that the KLF4 binding region in human IL-36γ promoter is conserved in the 
rhesus monkey and chimpanzee, but not in the mouse or rat, whereas the sequence of the IL-
36γ promoter region corresponding to the p65 binding site is approximately 70% conserved in 
mice and rat as compared to humans (Supplemental Figure 3D and refs. 40, 41). Alignment of the 
mouse and human IL-36γ gene loci revealed furthermore that the mouse genome lacks the 
region corresponding to the 583 bp long-region of human IL-36γ that contains the KLF4 
binding site (-1120 bp) (Supplemental Figure 3E). These results demonstrate that the mouse 
IL-36γ promoter is devoid of the KLF4 binding site found in humans, explaining the absence 
of synergistic induction of IL-36γ expression by EGFR inhibition and NF-κB activation in 
murine keratinocytes, and suggests that the mouse is not an appropriate model for the in vivo 
analysis of the acneiform skin toxicity to EGFRi. 
Blockade of the EGFR-MEK-ERK pathway results in elevated KLF4 and IL-36γ expression 
MEK inhibitors, which block the MAPK-ERK signaling pathway by inhibiting the MAP 
kinases MEK1 and MEK2, cause adverse skin reactions similar to those observed in EGFRi-
treated patients, including the commonly observed acneiform skin toxicity (4). Quantitative 
PCR analysis of acneiform lesional skin biopsies from MEKi-treated patients revealed, as 
observed in EGFRi-treated patients, elevated IL-36γ (9.4-fold, p=0.0012) and IL-8 (15-fold, 
p=0.019), but not IL-1β or IL-6 mRNA levels (Figure 4A and Supplemental Figure 4A). 
Since MEK is a downstream partner in the EGFR signaling pathway, we next assessed 
whether MEK inhibition could also result in elevated IL-36γ gene expression in PHKs. In 
vitro, the MEK inhibitors trametinib and selumetinib, together with C. acnes, synergistically 
induced elevated production of IL-36γ in PHKs, as previously observed with EGFRi (Figure 
4B left and Supplemental Figure 4B). Similar results were observed upon ERK silencing with 
siRNA (Supplemental Figure 4C). Of interest is the reported reduced incidence and severity 
of cutaneous skin toxicities observed in patients treated simultaneously with a BRAF inhibitor 
(BRAFi) and MEKi in clinical practice, as compared to patients treated with MEKi alone, and 
this has been shown to be due to paradoxical ERK activation in BRAF wild-type cells (42-
44). In line with this clinical observation, when PHKs were pre-exposed to the BRAFi 
vemurafenib prior to exposure to trametinib and C. acnes, the expression of IL-36γ mRNA 
induced by trametinib was significantly inhibited (7.4-fold, p=0.0002) (Figure 4B and 
Supplemental Figure 4D). 
Consistent with increased IL-36γ expression observed upon inhibition of the EGFR-
MEK-ERK pathway at different levels, elevated KLF4 expression was also observed (Figure 
4C-D). Furthermore, ERK1 and ERK2 could be co-immunoprecipitated with KLF4 from 
HEK293T cells transfected with FLAG-tagged KLF4 and Myc-tagged ERK1 and ERK2 
(Figure 4E), suggesting possible post-transcriptional modification of KLF4 by ERK1/2. 
Indeed, enhanced poly-ubiquitination (top panel) and phosphorylation of proline-neighboring 
serine or threonine residues (second panel) of KLF4 was observed in the presence of 
constitutively active ERK, and the latter is consistent with the activity of “proline-directed 
protein kinases” ERKs (45) (Figure 4F). To determine if KLF4 expression is regulated by 
ubiquitination and proteasomal degradation, expression in response to proteasome inhibition 
was analyzed. Indeed, increased KLF4 expression was observed upon proteasomal inhibition 
with MG132 (Supplemental Figure 4E), indicating that KLF4 expression is controlled also 
post-translationally, and targeted for proteasomal degradation after ERK1/2 phosphorylation, 
as a downstream consequence of EGFR-MEK pathway activation. These data show that 
inhibition of either EGFR or MEK signaling in keratinocytes elevates KLF4 expression post-
translationally (Supplemental Figure 4F).  
KLF4 enhances IL-36γ transcriptional activity upon EGFR/MEK inhibition 
To determine if KLF4 is capable of enhancing IL-36γ transcriptional activity, we 
overexpressed KLF4 in PHKs. Such an overexpression resulted in enhanced IL-36γ 
expression at the protein level upon exposure of PHKs to C. acnes (Figure 5A). Similarly, 
doxycycline-inducible overexpression of wild-type KLF4 enhanced IL-36γ transcriptional 
activity whereas dominant-negative KLF4 mutant did not (Figure 5B). This demonstrates that 
forced expression of KLF4 can alone mimic the effect of EGFR/MEKi to drive IL-36γ 
production in keratinocytes. In accordance with this, siRNA silencing of KLF4 substantially 
suppressed the ability of EGFRi and C. acnes to enhance IL-36γ production (Figure 5C). The 
deletion of KLF4 in keratinocyte cell lines using the CRISPR/Cas9 system resulted in a loss 
of induction of IL-36γ gene expression in response to MEKi (Figure 5D and Supplemental 
Figure 5A). Furthermore, mutation of the KLF4-binding site in keratinocyte cell lines by 
CRISPR/Cas9 abrogated the ability of MEKi to induce IL-36γ transcription, whereas in these 
cell lines IL-1β expression was unaffected (Figure 5E). This demonstrates an essential role of 
KLF4 and its binding to the IL-36γ promoter in regulating IL-36γ transcriptional activity.  
Consistent with a previous report (46), inhibition of the EGFR-MEK-ERK pathway 
resulted in increased KLF4 expression in the nucleus of PHKs in vitro (Figure 6A). In 
acneiform skin lesions from EGFRi treated patients, abundant nuclear KLF4 expression could 
be observed in keratinocytes. In contrast, only low levels of nuclear KLF4 expression was 
observed in control skin samples (Figure 6B-C). This data suggests that inhibition of either 
EGFR or MEK signaling enhances nuclear KLF4 expression in keratinocytes in the skin.  
Discussion 
Here we demonstrate that EGFR and MEK inhibitors partner with the commensal bacterium 
C. acnes that colonizes sebum rich skin to potently induce keratinocyte IL-36γ expression and 
drive IL-8-mediated neutrophil rich inflammation, the pathogenic hallmark of the so called 
“acneiform” skin toxicity frequently associated with these targeted agents. On the basis of in 
vitro and ex vivo investigations we pinpoint the regulation of keratinocyte IL-36γ expression 
upon EGFR blockade to two important signaling events. First, an upregulation of the 
expression and subsequent binding of the transcription factor KLF4 to its binding site in the 
promoter region of IL-36γ, and second, a signal provided by C. acnes resulting in the binding 
of NF-κB p65 to a sequence in close proximity to the above-mentioned KLF binding site. 
Interestingly, the simultaneous binding of these two transcription factors to the IL-36γ 
promoter results not only in an additive but in a synergistic effect on IL-36γ gene 
transcription, which is of relevance for the characteristic localization of the EGFRi induced 
rash to sebum-rich regions of the skin densely populated with pilo-sebaceous units and C. 
acnes such as the central face, upper chest, and back (17-22). Beyond the topographical 
distribution of the skin eruption, clinical practice guidelines for therapy support the 
involvement of C. acnes in the pathogenesis of acneiform skin toxicity by EGFR/MEKi. Such 
guidelines recommend systemic treatment using tetracyclins such as doxycycline or retinoids 
such as acitretin (47), both of which exert an antibacterial effect on C. acnes, either directly 
for the former, or indirectly by reducing sebum production leading to an alteration of the 
follicular micromilieu and an indirect reduction in C. acnes counts by up to 3 log (48). 
 As previously reported, the dysfunction of skin barrier and antimicrobial peptide 
production resulting from EGFR signaling abrogation are important events that can cause 
severe skin inflammation (13, 14). It is unclear, however, to what extent this may contribute 
to the initiation of acneiform skin toxicity by EGFR/MEKi, possibly by facilitating the 
penetration of commensals such as C. acnes into the epidermis and/or pilo-sebaceous unit. 
Indeed, a possible involvement of other stimuli in addition to EGFR inhibition are suggested 
in skin rash development of a mouse model (49). KLF4 has been demonstrated to be a key 
driver of terminal epidermal differentiation in the skin (50). The enhanced differentiation 
induced by increased KLF4 in response to EGFR/MEK inhibition might be an important 
event leading to the skin barrier dysfunction. KLF4 has only rarely been mentioned to be 
related to inflammatory diseases, but is known as a regulator of proinflammatory cytokine 
expression in rheumatoid arthritis (51), and is one of the susceptibility genes for psoriasis (52, 
53), two diseases in which IL-36γ is significantly increased in the inflamed tissues (54-57). 
Indeed, elevated expression of KLF4 has been reported in synovial tissue from rheumatoid 
arthritis patients and in the epidermis of psoriatic skin (51, 58), but the exact role of KLF4 in 
the pathogenesis of these inflammatory diseases remains to be defined.  
IL-36γ has been demonstrated to form a self-amplifying inflammatory loop in 
keratinocytes which express high levels of the IL-36 receptor (34, 59). Besides DITRA, there 
is accumulating evidence that IL-36 signaling plays an important role in various neutrophilic 
dermatoses including generalized pustular psoriasis (GPP), palmo-plantar pustular psoriasis 
(PPP), acute generalized exanthematous pustulosis (AGEP) and acrodermatitis continua 
Hallopeau (60, 61). The data presented here provides substantial evidence that acneiform skin 
toxicity caused by EGFR/MEKi should be added to the growing list of pustular skin diseases 
in which IL-36 likely plays a central pathogenic role. Our findings provide a basis for 
understanding the physiopathology of acneiform skin toxicity by caused EGFR/MEKi that 
may lead to better benefit from the antitumor effects with reduced side effects. Several IL-36 
inhibitors have been developed and Phase 2 clinical trials of anti-IL-36 receptor antibody in 
patients with GPP and PPP are ongoing, suggesting that the latter may also offer a possibility 
for targeted therapy of acneiform skin toxicities by EGFR/MEKi in the near future.  
 
Materials and Methods 
Human skin samples: Biopsies were obtained from lesional skin of EGFR and MEK 
inhibitor-treated patients with acneiform eruption. Normal skin was obtained from specimens 
from the Plastic Surgery Department. All biopsies were immediately frozen in liquid nitrogen 
and stored at -80°C for RNA extraction or directly fixed in Formalin (4% (g/v)) for at least 24 
hours for histology.  
Mice: Klf4-floxed mice were obtained from MMRRC (Columbia, MO). Rosa26-CreERT2 
mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Tamoxifen-inducible 
Klf4 knockout mice were generated by crossing Rosa26-CreERT2 mice and Klf4-floxed mice. 
Klf4 was knocked out by daily i.p. injection of tamoxifen at a dose of 100 mg/kg for five 
consecutive days. Wild-type C57BL/6 mice were obtained from Janvier labs (Le Genest-
Saint-Isle, France).  
Cell culture: Primary human keratinocytes were cultured as previously described (62). 
Briefly, primary human keratinocytes were isolated from fresh, surgically resected human 
neonatal foreskin. Keratinocytes were grown in keratinocyte serum free medium (#17005-
042, Thermo Scientific, Waltham, MA), supplemented with EGF and BPE (Thermo 
Scientific) and seeded for experiments after 3 passages. All cells were maintained at 37 °C in 
a 5% CO2 humidified atmosphere. Primary mouse keratinocytes were isolated from pooled 
ear and tail. Briefly, skin specimens were incubated with the dermal side down at 37°C in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1.25% trypsin (Sigma-
Aldrich, St. Louis, MI) and antibiotic-antimycotic solution (Gibco BRL, Paisley, Scotland) 
for 30 minutes. Separated epidermis was minced with sterile scissors and incubated at 37°C in 
DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) and 0.25 mg/ml DNase I for 
30 minutes, followed by filtration through a 70 µm cell strainer (BD Biosciences, San Jose, 
CA). Cells were resuspended in fresh keratinocyte serum free medium (#10744-019, Thermo 
Scientific) containing 50 ng/ml EGF (#E4127, Sigma-Aldrich), 10-10 M cholera toxin 
(#C8052, Sigma-Aldrich) and antibiotic-antimycotic solution (Gibco BRL) and seeded in 
Corning® Collagen I (15 µg/cm2,  #354236, Corning, NY)-coated dishes. After one day of 
attachment, non-adherent cells were washed away and fresh medium was added. HEK293T 
cells were cultured in DMEM supplemented with 10% (v/v) FBS, antibiotic-antimycotic 
solution (Gibco BRL), sodium-pyruvate (Invitrogen, Carlsbad, CA) and GlutaMAX solution 
(Invitrogen). Puromycin (#P9620) and blasticidin (#15205) were from Sigma-Aldrich.   
Plasmids: Human genomic DNA was isolated from primary human keratinocytes by 
QIAamp® DNA Mini Kit (QIAGEN, Venlo, Netherlands). The 6782 bp upstream sequence 
from the first ATG of human IL-36γ gene was amplified using Pfu polymerase (Invitrogen) 
with primers (forward; 5’-cacctgggcatattgcataatgg-3’, reverse; 5’-aagcttagtgtggttgtctcagcac-
3’, excluding an additional flanking BglII/HindIII site) and cloned into a luciferase reporter 
vector pGL3-Basic (Promega, Fitchburg, WI). The human IL-36γ promoter (1630 bp) 
luciferase construct and its NF-κB mutant construct were gifts from Professor Heiko Mühl 
(Goethe Universitz Frankfurt, Germany). Site-directed mutagenesis was performed using pfu 
Turbo (Thermo Scientific) according to manufacturer’s instructions to generate a point 
mutation in the EGFR inhibition-responsive site. Sequentially shorter reporter constructs of 
the human IL-36γ promoter were generated from the human IL-36γ promoter (1630 bp) 
construct, using following forward primers excluding an additional flanking BglII site; 5’-
ccatgtggatggagctgaaa-3’ (1180 bp); 5’-gcctggctttccattcaggt-3’ (1135 bp); 5’-
gtggggtagttgagaaatgc-3’ (1105 bp); 5’-cttgcctgagacgtgtggct-3’ (1076 bp). The dominant-
negative human KLF4 construct was generated from human KLF4 construct (Addgene 
#26815, Cambridge, MA), using a following reverse primer excluding additional restriction 
enzyme site; 5’-aaagaggggaagacgatcgtaa-3’. The following plasmids were purchased from 
Addgene and cloned into pcDNA3.1 (Invitrogen) or pMXs-IP (Gift from Prof. Kitamura, 
University of Tokyo, Japan); mouse Klf4 (Addgene #15920), human ERK1 (#23509), human 
ERK2 (#23498) and human ubiquitin (#31815). The constitutive active (CA)-ERK plasmid 
was a gift from Prof. Westermarck (University of Turku, Finland).  
Reagents: Erlotinib was purchased from MedChem Express (Monmouth Junction, NJ). 
Cetuximab was from MERCK Serono (Darmstadt, Germany). Trametinib and vemurafenib 
were from ApexBio (Boston, MA). Selumetinib and MG132 were from Selleckchem 
(Houston, TX). Recombinant human IL-36γ (#6835), mouse IL-36γ (#6996) and human IL-
36Ra (#1275) were from R&D systems (Minneapolis, MN). Pam3CSK4 was from InvivoGen 
(San Diego, CA). The goat anti-IL-36γ (#AF2320) and anti-mouse KLF4 (#AF3158) 
antibodies were from R&D systems (Minneapolis, MN). The rabbit anti-IL-36γ 
(#LS‑C201142) and its blocking peptide (#LS-E45854) were from LifeSpan BioSciences 
(Seattle, WA). The anti-human KLF4 antibody (#AM09057PU-N) was from Acris 
(Germany). The anti-β-actin, anti-FLAG (#F1804) and anti-myc (#C3956) antibodies were 
from Sigma-Aldrich. The anti-human KLF4 (#12173), anti-ERK (#9107), anti-phospho-ERK 
(#4370), anti-phospho-threonine/proline (#9391) antibodies were from Cell Signaling 
Technology (Danvers, MA). The anti-T7 antibody was from Abcam (#ab9138, Cambridge, 
UK). The anti-HA antibody was from Santa Cruz Biotechnology (#sc-805, Santa Cruz, CA). 
The secondary antibodies used were alkaline phosphatase-conjugated mouse IgG (#S372B), 
rabbit IgG (#S373B) and goat IgG (#V115A) from Promega. Live C. acnes was prepared as 
previously described (63). 
Gene expression array: Total RNA was extracted from individual skin samples using Tri-
Reagent (Sigma-Aldrich) according to manufacturer’s instructions. 1 µg of each RNA sample 
was converted to complementary DNA with RT2 First Strand kit (Qiagen) and used in real-
time PCR performed on Human Inflammatory Response & Autoimmunity RT² Profiler™ 
PCR Array (PAHS-3803Z, Qiagen) according to manufacturer’s protocol. Data analysis was 
performed using ΔΔCt method.  
Quantitative PCR: Complementary DNA was generated from total RNA using RevertAid 
First Strand cDNA Synthesis Kit (Thermo Scientific) according to manufacturer’s 
instructions. Quantitative real-time PCR was performed using a LightCycler®480 (Roche, 
Basel, Switzerland) with SYBR Green I Master mix (Roche). The primers used for 
amplification of specific genes were synthesized by Microsynth (Balgach, Switzerland) 
(Supplemental Table 2). 
In situ hybridization: 620 nucleotide-long human IL-36γ cDNA was amplified using Pfu 
polymerase (Invitrogen) with primers (forward; 5’-ggaagctgctggagccacgattc-3’, reverse; 5’-
aaagaccaagctgccacctctagg-3’, excluding an additional flanking HindIII/EcoRI site) and cloned 
into pcDNA3 vector (Invitrogen). PCR fragments for probes were amplified with primers for 
CMV and BGH. The digoxigenin (DIG)-labeled antisense and sense RNA probes for human 
IL-36γ were synthesized by in vitro transcription using either SP6 or T7 RNA polymerase 
with the DIG RNA labeling kit (Roche). These probes were hydrolyzed in hydrolysis buffer 
(40mM NaHCO3, 60mM Na2CO3) to be 0.25 kb. The unincorporated nucleotides were 
removed using a spin column (Roche). Formalin-fixed paraffin-embedded tissue sections (4 
μm) were deparaffinized and rehydrated in RNase-free condition. Sections were treated with 1 
μg/ml proteinase K for 20 minutes and washed with 2xSSC for three times, followed by 
prehybridization for 2 h in 2xSSC containing 50 % formamide. Hybridization buffer (HB) 
contained 50% formamide, 4xSSC, 100 ng/ml yeast tRNA and 10% dextran sulfate. 25 ng 
DIG-labeled RNA probes were diluted in 50 μl HB, heated to 95 °C for 5 minutes, added to 
the tissues and hybridized overnight. After hybridization, the tissues were washed and 
incubated in stringent wash buffer (20% formamide, 2xSSC) at 42 °C for 30 minutes, 
followed by 2 μg/mL RNase A treatment at 37 °C for 1 hour. The sections were washed in 
2xSSC and 0.2xSSC at 55°C each for 30 minutes and PBS at RT for 5 minutes. Blocking was 
performed in 5% BSA in PBS at RT for 1 h and sections were incubated in AP-conjugated 
anti-DIG Fab fragment (1/4000 dilution; Roche) at RT for 2 hours. After three washes in PBS 
for 5 minutes, tissues were stained using 2% NBT/BCIP in 0.1M NaCl, 0.1M Tris-HCl (pH 9) 
at RT in the dark for two days.  
Immunohistochemistry: 5 µm formalin-fixed, paraffin-embedded human skin sections were 
deparaffinized and rehydrated. Antigen unmasking was performed by heating the slides for 25 
minutes in Target Retrieval solution (DAKO, Glostrup, Denmark). Sections were blocked 
using 5% BSA in PBS for 1 hour and stained for 2 hours at room temperature with anti-IL-
36γ antibody. Primary antibodies were detected using a biotin-conjugated secondary antibody 
(Southern Biotech, Birmingham, USA) followed by an Avidin-Biotin-complex and addition 
of peroxidase substrate (Vector Laboratories, Peterborough, UK). Nuclei were counterstained 
using a solution of hematoxylin. The sections were mounted in mounting medium (DAKO, 
Santa Clara, CA) and imaged using an Aperio ScanScope (Leica Biosystems, Wetzlar, 
Germany). 
Immunofluorescence staining: PHKs were seeded on circular 18-mm glass coverslips 
(Hecht-Assisten, Sondheim/Rhön, Germany). Cells were fixed for 30 minutes in 3% 
paraformaldehyde/2% sucrose solution, permeabilized for 2 minutes with 0.2% Triton X-100 
in phosphate buffered saline and blocked for 1 hour in 1% bovine serum albumin (BSA 
Fraction V; GE Healthcare) in 0.5% Tween-20 in PBS. In vitro keratinocyte samples were 
stained for 2 hours at room temperature with anti-KLF4 goat antibody followed by 
DyLight488-conjugated secondary antibody (ab96891; Abcam, Cambridge, MA). Skin tissue 
samples were prepared as described in the immunohistochemistry paragraph. The sections 
were stained for 2 hours at room temperature with anti-KLF4 mouse antibody and anti-IL-36γ 
rabbit antibody followed by Alexa Fluor 488/555-conjugated secondary antibodies (A-11001, 
A-21429; Thermo Scientific). Nuclei were counterstained with DAPI. The sections were 
mounted in the mounting medium and imaged using an Aperio ScanScope (Leica Biosystems, 
Wetzlar, Germany). 
Western blot: To prepare whole cell lysates, cells were lysed in SDS buffer with DTT 
(Sigma-Aldrich). Proteins were separated on SDS-PAGE gels with Mini-PROTEAN Tetra 
Vertical Electrophoresis Cell (Bio-Rad Laboratories, Inc., Hercules, CA) at a constant voltage 
(80-120V) and transferred to an Amersham Protran 0.2 μm nitrocellulose membrane (GE 
Healthcare) using semi-dry or wet systems from Bio-Rad. The membranes were blocked with 
5% dried milk in PBS supplemented with 0.5% Tween-20 (Sigma-Aldrich) and then probed 
overnight with primary antibodies at 4 °C followed by AP-conjugated secondary antibodies 
for 1 hour at room temperature. Proteins were detected using BCIP/NBT color development 
substrate (Promega) and dried membranes were scanned using a LiDE210 scanner (Canon 
Inc., Tokyo, Japan).  
ChIP-seq/DNase-seq/RNA-seq data analysis: Raw sequencing data were converted to Fastq 
files by NCBI SRA Toolkit. Quality control on the raw data was performed by FastQC. The 
reads for ChIP-seq/DNase-seq were aligned to human reference genome (build 
GRCh37/hg19) by Bowtie2 Aligner. The mapped sequence reads were transformed to a 
binary format, sorted and indexed by SAMtools, followed by generation of coverage plots by 
BEDtools. These files were converted into BigWig files by BedGraphtoBigWig and 
visualized in IGV. ChIP-seq data from primary human keratinocytes were obtained from the 
following ChiP-seq/DNase-seq samples: GSM941735, GSM733698, GSM733674, 
GSM733636 and GSM816635.  ChIP-seq data of p65 was from GSM935526. The reads for 
RNA-seq were aligned to human reference genome (build GRCh37/hg19) by HISAT2. The 
transcripts were assembled by Cufflinks, followed by generation of differential gene 
expression data by Cuffdiff. RNA-seq data from primary human keratinocytes were obtained 
from GSM2074746, GSM2074747 and GSM2074748.  
Luciferase reporter assay: Human and mouse primary keratinocytes were transfected with 
reporter constructs using TransIT-X2® Dynamic Delivery System (Mirus Bio, Madison, WI) 
according to manufacturer’s instructions. Co-transfection of the Renilla-luciferase expression 
vector pRL-TK (Promega, Fitchburg, WI) was used as an internal control for all reporter 
assays. Cell extracts were generated 24 hours post transfection using Reporter Lysis Buffer 
(Promega) and extracts were assayed for firefly luciferase and Renilla-luciferase activity 
using the Luciferase Assay system (Promega) and coelenterazine (0.1 μg/ml, Sigma-Aldrich), 
respectively. Luminescence was measured with the Cytation3 Imaging Reader (BioTek, 
Winooski, VT).  
Gene Transfer and knockdown: HEK293T cells were transfected with 8 μg of mammalian 
expression construct of human and mouse KLF4 using TransIT-X2® Dynamic Delivery 
System (Mirus Bio). Primary human keratinocytes were transduced using a published 
protocol (64) with minor modifications. Briefly, viral supernatant was produced by 
transfecting 8 μg of KLF4-pMXs-IP to Phoenix Ampho cells (ATCC, Manassas, VA) using 
TransIT-X2® Dynamic Delivery System (Mirus Bio). Viral supernatant was collected 48 
hours after transfection and added to keratinocytes in 6-well plates supplemented with 10 
μg/mL polybrene (Sigma-Aldrich) followed by centrifugation at 650 g for 45 minutes at 
32°C. After centrifugation, keratinocytes were washed with PBS and cultured in fresh 
medium. The same transfection step was repeated in the next day and keratinocytes were 
incubated another 24 hours for experiments. Mouse keratinocytes were transfected in 12-well 
plates with 3 μg of mammalian expression construct of mouse KLF4 using the TransIT-X2® 
Dynamic Delivery System (Mirus Bio). Silencing RNA (siRNA) transfection of primary 
human keratinocytes was carried out using INTERFERin (Polyplus-transfection, Illkirch, 
France) at a final concentration of 5 nM endoribonuclease-prepared siRNA (esiRNA) 
according to manufacturer’s protocol. The esiRNAs used (EGFR, KLF4, ERK1, ERK2) were 
purchased from Sigma-Aldrich. Experiments were performed 2 days after transfection. EGFP 
esiRNA was used as a control. Short hairpin RNA (shRNA) fragments of human TLR2 were 
hybridized with synthesized sense and anti-sense oligonucleotides. The sense strand sequence 
is 5’-ccggccagccagaaagcactacaatctcgagattgtagtgctttctggctggttttt-3’. DNA oligonucleotides 
were synthesized by Microsynth and ligated into Tet-pLKO-puro (Addgene #21915). Viral 
supernatant was produced by transfecting the Tet-pLKO-puro plasmid, psPAX2 (Addgene, 
#12260) and pMD2.G (Addgene, #12259) into HEK 293T cells and viruses were harvested 48 
hours later. KERTr keratinocyte cell lines (ATCC CRL-1658, Manassas, VA) were 
transduced with the virus and selected for 1 week with 1 μg/ml puromycin. Gene knockdown 
was induced by culturing the cells in the medium containing 1 μg/ml doxycycline. 
Generation of CRISPR/Cas9-cell lines: Single-stranded DNA oligonucleotides 
(Supplemental Table S3) were cloned into pLentiCRISPRv2 plasmid (Addgene, #98293). 
Viral supernatant was produced by transfecting the pLentiCRISPRv2 plasmid, psPAX2 and 
pMD2.G into HEK 293T cells and viruses were harvested 48 hours later. KERTr keratinocyte 
cell lines were transduced with the virus and selected for 10 days with 10 μg/ml blasticidin. 
Cloning was performed by limiting dilution in conditioned medium. Genomic DNA was 
extracted from the isolated single cell-expanded clones using QIAamp DNA Mini Kit and 
amplicons harboring the targeted alleles were prepared by PCR using Taq polymerase 
(#EP0404, Thermo Scientific). The PCR amplicons were cloned into a TOPO vector using 
TA Cloning Kit (Promega) according to the manufacturer’s protocol and then sent for Sanger 
sequencing.  
EMSA: The sequences of the probes used for EMSA were; EGFR inhibition-responsive site 
wild-type forward; 5’-ttccattcaggtgtggccttag-3’, wild-type reverse; 5’- 
ctaaggccacacctgaatggaa-3’, mutant forward; 5’-ttccattcaaatgtggccttag-3’, mutant reverse; 5’- 
ctaaggccacatttgaatggaa-3’, putative murine KLF4 binding site forward; 5’-
gagatccaggtggaaaggaaga-3’, and reverse; 5’-tcttcctttccacctggatctc-3’. The probes including 
Cy3-modification at the 5’ end were synthesized by Microsynth. To construct oligonucleotide 
duplexes, 2 nmol of each sense and antisense oligonucleotides were annealed in a buffer (100 
mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2 and 100 μg/ml BSA) by heating the mixtures to 
95°C for 5 minutes and allowing the solution to cool slowly to room temperature. EMSA was 
performed with 5 μg of cell lysate, 0.15 pmol of Cy3-labeled oligonucleotides, 1.5 μg of 
BSA, 0.5 μg of poly(dI-dC) and in 12 μl of reaction mixture (24 mM HEPES-KOH pH 7.9, 8 
mM Tris-HCl (pH 8.0), 2 mM EDTA, 1 mM DTT and 12% glycerol) with a proteinase 
inhibitor cocktail (Roche). Competition assays were performed to demonstrate the sequence 
specific binding of the probes. For the competition assays, a 50-fold molar excess of 
unlabeled wild-type or mutant oligonucleotide probe was added 20 minutes before the 
addition of Cy3-labeled probes and incubated for another 20 minutes at room temperature. 
Supershift assays were performed to demonstrate the complex formation of the protein of 
interest and the target probe, by means of appearance of a new supershifted band upon 
addition of antibody targeting the protein of interest.  For the supershift assays, 1 μg of anti-
KLF4 antibody (Cell Signaling Technology) was added to the reaction mixture for 20 minutes 
before the addition of Cy3-labeled probes. Samples were loaded onto Novex® 6% DNA 
retardation gels (Thermo Scientific) and subjected to electrophoresis in 0.5X Tris borate 
buffer for 30 minutes at 150 mV. Gels were subsequently visualized on an Odyssey® Fc 
Imaging System (LI-COR Biosciences, France).  
DNA pull down assay: The sequences of the probes used for the DNA pull down assay were 
the same as those for EMSA. 5’-biotinylated wild-type and mutant forward oligonucleotides 
were synthesized by Microsynth and annealed with non-biotinylated reverse oligonucleotides. 
Cell lysates were incubated in the same reaction buffer as EMSA with 7.5 nmol of double-
stranded annealed oligonucleotides at 4°C overnight with gentle shaking on a rocker. 30 μl of 
Pierce™ High Capacity Streptavidin Agarose beads (Thermo Scientific) was added and 
incubated at 4°C for 1 hour. Beads were washed five times with ice-cold PBS using 
SigmaPrep™ spin column (Sigma-Aldrich). Proteins bound to streptavidin beads were 
dissolved in 2x SDS sample buffer, boiled at 95 °C for 5 minutes and subjected to 
immunoblotting. 
Co-immunoprecipitation analysis: HEK293T cells were transfected in 6-well plates with 
2.4 μg of plasmids (Myc-tagged ERK1 (0.4 μg) and ERK2 (2 μg) and FLAG-tagged KLF4 
(0.4 μg); HA-tagged ubiquitin (0.8 μg), FLAG-tagged KLF4 (0.8 μg) and CA-ERK (0.8 μg)) 
using TransIT-X2® Dynamic Delivery System (Mirus) according to manufacturer’s 
instructions. Empty vector pcDNA3.1 was added to be 2.4 μg of plasmids in total. 24 hours 
after transfection, cells were washed with ice-cold PBS and lysed with pre-chilled lysis buffer 
(50 mM Tris-Hcl (pH 7.5), 100 mM NaCl and 0.1% (v/v) Triton-X supplemented with 
protease and phosphatase inhibitor cocktail (Roche) for 30 minutes on a rocker at 4 °C. 
Samples for ubiquitin analysis were boiled at 95°C for 5 minutes in 1% SDS and sample 
buffer was added to dilute to 0.1% SDS. Samples were incubated overnight with anti-FLAG 
(1 μg) at 4 °C, followed by the addition of 30 μl protein A/G PLUS Agarose beads (Santa 
Cruz Biotechnology) and incubation for 2 hours. Immunoprecipitates were collected by 
centrifugation at 1,000 g for 5 minutes at 4 °C and the beads were then washed five times with 
lysis buffer. The beads were resuspended in 2x SDS sample buffer, boiled at 95 °C for 
5 minutes and subjected to immunoblotting. 
ELISA: Primary human keratinocytes were exposed to 1 μM erlotinib and 5 μg/mL 
Pam3CSK4 in 6-well plates for 48 hours. After washing three times with pre-warmed PBS, 
cells were incubated in fresh medium for 48 hours. After centrifugation, supernatants were 
collected and subjected to IL-36γ ELISA (Adipogen, Lausanne, Switzerland).  
Ex vivo skin culture: Ex vivo skin culture was performed using a published protocol (65) 
with the following modifications. Full-thickness skin specimens were obtained from patients 
undergoing plastic or reconstructive surgery. Skin samples were cut to small pieces (4 x 4 
mm) and placed in 24-well plates containing 0.5 ml of keratinocyte serum free medium 
(#17005-042, Thermo Scientific) supplemented with EGF, BPE (Thermo Scientific), 100 
μg/mL kanamycin (Invitrogen) and 1.4 mM CaCl2  (Sigma-Aldrich). Tissue cultures were 
then incubated at 37 °C in a 5% CO2 atmosphere with fresh culture medium provided at 2 day 
intervals. Ex vivo skin explants were cultured with 1 μg/mL erlotinib for 24 hours for western 
blotting or for 4 days followed by snap freezing for subjecting to quantitative PCR.  
Statistical analysis: Statistical analysis was performed using unpaired Student’s t-test or one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple-comparison test, using 
Prism 7.02 software (GraphPad, La Jolla, CA). Differences were considered significant when: 
*P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001. 
Study approval: All experiments with human samples and the use of human skin samples for 
research studies were carried out in accordance with the Cantonal Ethical Committee of 
Zurich, Switzerland after informed written patient consent and according to the Declaration of 
Helsinki Principles. All animal procedures were approved by the Cantonal Veterinary Office 
of Zurich, Switzerland. 
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Figure 1: Increased production of IL-36γ in primary keratinocytes and lesional skin of 
patients suffering from acneiform eruptions in response to EGFR inhibition and C. 
acnes. (A) Gene expression profiling from lesional skin of five patients and five healthy 
control (HC). Heatmap of the top 12 most differentially expressed genes ranked from lowest 
false discovery rate (FDR) and 12 selected genes are shown. (B) Quantitative PCR of mRNA 
from lesional skin samples of 10 EGFR inhibitor-treated patients with acneiform eruption and 
10 healthy control skin biopsies. Data represent mean (SD). (C) Immunohistochemistry 
staining with goat anti-IL-36γ antibody of formalin-fixed paraffin-embedded skin sections of 
acneiform eruption patient and normal donors. Scale bar represents 100 μm. Pictures are 
representative of five patients and five healthy individuals. (D) PHKs were exposed to 
erlotinib (EGFR inhibitor, 1 μM) and C. acnes (MOI of 10) for 6 hours. Total RNA was 
subjected to qPCR analysis. Data represent means ± SEM. n = 3. (E) PHKs were exposed to 
either erlotinib (1 μM) or C. acnes (MOI of 10) or both for 24 hours. Cell lysates were 
subjected to western blotting using specific antibodies to IL-36γ and β-actin. Blots were run 
contemporaneously with the same protein samples. (F) PHKs were exposed to erlotinib (1 
μM) and Pam3CSK4 (5 μg/mL). IL-36γ secretion was measured by ELISA in culture 
supernatants. Data represent means ± SEM. n = 3. (G) Ex vivo skin explants were exposed to 
erlotinib (1 μM), Pam3CSK4 (5 μg/mL) and/or human IL-36Ra (1 μg/mL). The skin samples 
were then subjected to quantitative PCR. Data represent means ± SEM. n = 4. Data were 
analyzed with 2-tailed unpaired t test (B), 1-way ANOVA followed by Dunnett’s (D and F) or 
Tukey’s multiple-comparisons test (G). *P<0.05, **P<0.01, ***P<0.001. Data are 
representative of 3 independent experiments.  
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Figure 2. KLF4 binds to the IL-36γ promoter and regulates IL-36γ transcriptional 
activity in response to EGFR inhibition. (A) Luciferase reporter assay of human IL-36γ 
transcriptional activity in PHKs transfected with IL-36γ-pGL3 (1630 bp) reporter plasmid, 
followed by exposure to erlotinib and C. acnes for 16 hours. TK Renilla luciferase was 
measured to determine transfection efficiency. Data represent means ±SEM. n=4. (B, D) 
Schematic of 5’-deletion and mutant constructs of the human IL-36γ promoter. Site-directed 
mutagenesis was performed to introduce the indicated mutation at the EGFR inhibitor-
responsive site (EiRS) and p65 binding site. (C, E) 5’-Deletion and mutation study of the 
human IL-36γ promoter activity. PHKs were transfected with indicated plasmids, followed by 
exposure to erlotinib and C. acnes for 16 hours. n=4, Data represent means ±SEM. (F) RT-
PCR was performed to evaluate the gene expression of transcription factor candidates binding 
to the EiRS. PHKs were exposed to erlotinib for 6 hours. Data represent means ±SEM. n=3. 
(G) Gel shift, competition and supershift EMSA analysis using Cy5-labeled oligonucleotide 
probe of the EiRS-containing region and HEK293T cell lysate containing KLF4 protein. (H) 
PHKs were exposed to erlotinib and C. acnes for 24 hours. (I) DNA pull-down assay using 
biotinylated wild-type- or mutant-oligonucleotide probe of the EiRS-containing region. These 
probes were incubated with extracts from PHKs exposed to erlotinib for 24 hours. DNA-
associated proteins were visualized by western blotting. (J) Ex vivo skin explants from 
healthy controls were exposed to erlotinib for 24 hours and KLF4 expression was assessed by 
western blotting. The blot shown is representative of two different skin donors. Data were 
analyzed with 1-way ANOVA followed by Dunnett’s multiple-comparisons test (A and E) or 
with 2-tailed unpaired Mann-Whitney U (C) or t test (F). *P<0.05, **P<0.01, ***P<0.001. 
All blots were run contemporaneously with the same protein samples. 
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Figure 3. Lack of KLF4 binding site results in loss of synergistic IL-36γ production in 
mice. (A) PMKs were exposed to erlotinib (1 μM) and murine IL-36γ (100 ng/mL) for 6 
hours, isolated RNA was subject to qPCR. Data represent means ± SEM. n = 3. (B) PMKs 
from wild-type or KLF4 knockout mouse were exposed to murine IL-36γ (100 ng/mL) for 6 
hours. Data represent means ± SEM. n = 3. PMK cell lysates were subject to SDS-PAGE and 
immunoblotting. Blots were run contemporaneously with the same protein samples. (C) 
Schematic of the human and murine IL-36γ promoter with predicted KLF4 binding site and 
p65 binding site by JASPAR. (D) Gel shift and competition EMSA analysis using Cy5-
labeled oligonucleotide probe of human and mouse KLF4 binding sites and HEK293T cell 
lysate containing murine KLF4 protein. Sequence specific binding of human probe to murine 
KLF4 was demonstrated as a positive control. Gel shift reflecting formation of protein-DNA 
complexes with the murine probe and KLF4 was not observed. Data are representative of 3 
independent experiments.  
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Figure 4: Blockade of the EGFR-MEK-ERK pathway increases keratinocyte expression 
of KLF4. (A) Quantitative PCR was performed to evaluate gene expression in RNA isolated 
from biopsies of 4 patients with acneiform eruption and 10 healthy control skin biopsies. Data 
represent mean (SD). (B) PHKs were pre-exposed to the BRAF inhibitor vemurafenib (1 
μg/mL) for 30 minutes and exposed to the MEK inhibitor trametinib (2 μg/mL) and C. acnes 
(MOI of 10) for 6 hours. Data represent means ± SEM. n = 3. Data were analyzed with 2-
tailed unpaired t test (A) or 1-way ANOVA followed by Tukey’s multiple-comparisons test 
(B). *P<0.05, **P<0.01, ***P<0.001. (C) PHKs were exposed to erlotinib (1 μM) or 
trametinib (2 μg/mL) for 24 hours and total cell lysates were collected for western blotting 
with antibodies to KLF4 and β-actin. (D) ERK1 and ERK2 were silenced by siRNA in PHKs 
and cell lysates were subjected to SDS-PAGE and immunoblotting with indicated antibodies. 
(E) HEK293T cells were transfected with FLAG-tagged KLF4 and Myc-tagged ERK1 and 
ERK2 for 24 hours. Cell lysates were immunoprecipitated with an anti-FLAG antibody, 
followed by immunoblotting with the indicated antibodies. (F) HEK293T cells were 
transfected with FLAG-tagged KLF4, HA-tagged ubiquitin and constitutively active ERK for 
24 hours. Cell lysates were immunoprecipitated with an anti-FLAG antibody, followed by 
immunoblotting with the indicated antibodies. All blots were run contemporaneously with the 
same protein samples. Data are representative of 3 independent experiments. 
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Figure 5: KLF4 is critical for IL-36γ transcriptional activity upon EGFR/MEK 
inhibition. (A) KLF4 overexpressing primary keratinocytes were exposed to C. acnes for 24 
hours. (B) Flag-tagged wild-type (WT)- and dominant-negative (DN)-KLF4 were 
overexpressed in response to doxycycline using Tet-on system for 24 hours, followed by 
exposure to Pam3CSK4 for another 24 hours. The cell lysates were collected for western 
blotting and qPCR. Data represent means ± SEM. n = 3. (C) KLF4 siRNA-treated PHKs were 
exposed to erlotinib and C. acnes for 6 hours. Data represent means ± SEM. n = 3. (D) KLF4 
knocked out keratinocyte cell lines by CRISPR/Cas9 were exposed to trametinib (2 μg/mL) 
for 24 hours and total cell lysates were collected for western blotting with antibodies to KLF4 
and β-actin. The cells were exposed to trametinib for 24 hours and isolated RNA was subject 
to qPCR. Data represent means ± SEM. n = 3. All blots were run contemporaneously with the 
same protein samples. Data are representative of 3 independent experiments. (E) Mutations 
generated by CRISPR/Cas9 in the KLF4 binding site. Red nucleotides are the PAM sequence 
and blue nucleotides hybridize to the sgRNA. KLF4 binding site-mutant cells were exposed to 
trametinib and Pam3CSK4 for 24 hours. Total RNA was subjected to qPCR analysis. Data 
represent means ± SEM. n = 3. Data were analyzed with 1-way ANOVA followed by 
Dunnett’s (B and E) or Tukey’s multiple-comparisons test (C) or with 2-tailed unpaired t test 
(D). *P<0.05, **P<0.01, ***P<0.001.  
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Figure 6: Increased KLF4 level in vitro and in vivo upon EGFR inhibition. (A) 
Representative images of KLF4 expression (green) in PHKs after erlotinib or control DMSO 
exposure for 24 hours. Nuclei were stained with DAPI. Scale bar represents 10 μm. Data are 
representative of 3 independent experiments. (B-C) Immunofluorescence staining with mouse 
anti-KLF4 (green) and rabbit anti-IL-36γ (red) antibodies of formalin-fixed paraffin-
embedded skin sections of acneiform eruption patients and normal donors. Nuclei were 
stained with DAPI. The white box regions were zoomed separately in the figure C. Scale bar 
represents 50 μm (B) and 10 μm (C). Pictures are representative of five patients and three 
healthy individuals. 
 
 
